LSE - Delayed Quote GBp

Novacyt S.A. (NCYT.L)

69.00 +0.90 (+1.32%)
At close: April 26 at 4:29 PM GMT+1
Key Events
Loading Chart for NCYT.L
DELL
  • Previous Close 68.10
  • Open 67.00
  • Bid 68.00 x --
  • Ask 70.00 x --
  • Day's Range 66.64 - 69.80
  • 52 Week Range 35.80 - 86.00
  • Volume 100,012
  • Avg. Volume 82,782
  • Market Cap (intraday) 49.61M
  • Beta (5Y Monthly) -1.71
  • PE Ratio (TTM) --
  • EPS (TTM) -0.36
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.

www.novacyt.com

120

Full Time Employees

December 31

Fiscal Year Ends

Related News

Performance Overview: NCYT.L

Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

NCYT.L
12.20%
CAC 40
7.23%

1-Year Return

NCYT.L
32.44%
CAC 40
7.39%

3-Year Return

NCYT.L
84.43%
CAC 40
29.25%

5-Year Return

NCYT.L
253.85%
CAC 40
45.53%

Compare To: NCYT.L

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NCYT.L

Valuation Measures

Annual
As of 4/26/2024
  • Market Cap

    49.61M

  • Enterprise Value

    -31.74M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.19

  • Price/Book (mrq)

    0.45

  • Enterprise Value/Revenue

    -4.03

  • Enterprise Value/EBITDA

    2.14

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -5.88%

  • Return on Equity (ttm)

    -21.08%

  • Revenue (ttm)

    7.87M

  • Net Income Avi to Common (ttm)

    -25.3M

  • Diluted EPS (ttm)

    -0.36

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    81.74M

  • Total Debt/Equity (mrq)

    0.36%

  • Levered Free Cash Flow (ttm)

    -9.66M

Company Insights: NCYT.L

People Also Watch